Home Other Building Blocks Piperazin-2-one

Piperazin-2-one

CAS No.:
5625-67-2
Catalog Number:
AG003HW6
Molecular Formula:
C4H8N2O
Molecular Weight:
100.1191
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1g
98%
In Stock USA
United States
$13
- +
5g
98%
In Stock USA
United States
$19
- +
25g
98%
In Stock USA
United States
$57
- +
100g
98%
In Stock USA
United States
$163
- +
500g
98%
In Stock USA
United States
$600
- +
Product Description
Catalog Number:
AG003HW6
Chemical Name:
Piperazin-2-one
CAS Number:
5625-67-2
Molecular Formula:
C4H8N2O
Molecular Weight:
100.1191
MDL Number:
MFCD01318687
IUPAC Name:
piperazin-2-one
InChI:
InChI=1S/C4H8N2O/c7-4-3-5-1-2-6-4/h5H,1-3H2,(H,6,7)
InChI Key:
IWELDVXSEVIIGI-UHFFFAOYSA-N
SMILES:
O=C1CNCCN1
EC Number:
629-162-6
NSC Number:
27441
Properties
Complexity:
81.8  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
100.064g/mol
Formal Charge:
0
Heavy Atom Count:
7  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
100.121g/mol
Monoisotopic Mass:
100.064g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
41.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1.1  
Literature
Title Journal
Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency. Bioorganic & medicinal chemistry letters 20120115
Identification of novel sildenafil-analogues in an adulterated herbal food supplement. Journal of pharmaceutical and biomedical analysis 20111205
Discovery of potent, orally bioavailable phthalazinone bradykinin B1 receptor antagonists. Journal of medicinal chemistry 20111027
Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters 20110615
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation. Bioorganic & medicinal chemistry letters 20110601
A submarine journey: the pyrrole-imidazole alkaloids. Marine drugs 20091201
Ligand scaffold hopping combining 3D maximal substructure search and molecular similarity. BMC bioinformatics 20090101
Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. Journal of asthma and allergy 20090101
Computer applications for prediction of protein-protein interactions and rational drug design. Advances and applications in bioinformatics and chemistry : AABC 20090101
Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents. Journal of medicinal chemistry 20081009
Concise synthesis of the CDE ring system of tetrahydroisoquinoline alkaloids using carbophilic Lewis acid-catalyzed hydroamidation and oxidative Friedel-Crafts cyclization. The Journal of organic chemistry 20080704
Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorganic & medicinal chemistry letters 20080601
Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers. Bioorganic & medicinal chemistry 20080201
[Piperazines as model substrate for oxidations]. Die Pharmazie 20061001
New class of nucleophiles for palladium-catalyzed asymmetric allylic alkylation. Total synthesis of agelastatin A. Journal of the American Chemical Society 20060510
Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Organic & biomolecular chemistry 20060507
(13)C NMR spectral assignment of 1,4-diarylpiperazinones. Magnetic resonance in chemistry : MRC 20060101
Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitors III. Effect of ring opening of piperazinone moiety on inhibition. Chemical & pharmaceutical bulletin 20040401
Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & medicinal chemistry letters 20040209
Synthesis of a library of 3-oxopiperazinium and perhydro-3-oxo-1,4-diazepinium derivatives and identification of bioactive compounds. Journal of combinatorial chemistry 20040101
alpha-Keto amides as precursors to heterocycles--generation and cycloaddition reactions of piperazin-5-one nitrones. Organic & biomolecular chemistry 20030407
Synthesis of 1,4-diazines by ring expansion of 1,3-diazines. The Journal of organic chemistry 20030321
Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. Journal of medicinal chemistry 20030227
Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: synthesis and pharmacological evaluation of 2-oxopiperazine derivatives. Journal of medicinal chemistry 20010719
The design of competitive, small-molecule inhibitors of coagulation factor Xa. Current topics in medicinal chemistry 20010601
3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase. Organic letters 20010322
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase. Bioorganic & medicinal chemistry letters 20010226
Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors. Bioorganic & medicinal chemistry letters 20010212
Properties